Novo Nordisk A/S slashed its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...